Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CervoMed Inc. (CRVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: CRVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 126.81% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 59.61M USD | Price to earnings Ratio - | 1Y Target Price 15.83 |
Price to earnings Ratio - | 1Y Target Price 15.83 | ||
Volume (30-day avg) 164352 | Beta - | 52 Weeks Range 1.80 - 20.63 | Updated Date 06/23/2025 |
52 Weeks Range 1.80 - 20.63 | Updated Date 06/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.17 |
Earnings Date
Report Date 2025-06-13 | When After Market | Estimate -0.6233 | Actual -0.56 |
Profitability
Profit Margin -200.58% | Operating Margin (TTM) -276.55% |
Management Effectiveness
Return on Assets (TTM) -56.19% | Return on Equity (TTM) -93.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24369111 | Price to Sales(TTM) 6.4 |
Enterprise Value 24369111 | Price to Sales(TTM) 6.4 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.64 | Shares Outstanding 8702720 | Shares Floating 4930090 |
Shares Outstanding 8702720 | Shares Floating 4930090 | ||
Percent Insiders 33.38 | Percent Institutions 26.31 |
Analyst Ratings
Rating 4.57 | Target Price 15.83 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CervoMed Inc.
Company Overview
History and Background
CervoMed Inc. is a clinical-stage company focused on developing innovative therapies to treat neurological and neurodegenerative diseases. Founded in 2018, the company has rapidly advanced its lead product candidate, neflamapimod, into late-stage clinical trials.
Core Business Areas
- Drug Development: CervoMed focuses on the development and commercialization of therapies for neurodegenerative diseases.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The leadership team includes experienced executives and scientists in the pharmaceutical industry. The organizational structure is designed to support drug development and clinical operations.
Top Products and Market Share
Key Offerings
- Neflamapimod: Neflamapimod is CervoMed's lead investigational drug candidate, an oral small molecule brain-penetrant inhibitor of p38MAP kinase u03b1 (p38u03b1) for the treatment of neurodegenerative diseases. Currently in Phase 2b and Phase 3 clinical trials to treat Alzheimer's disease and dementia with Lewy bodies (DLB) respectively. Competitors include Biogen (Alzheimer's drugs).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurodegenerative diseases is growing, driven by an aging population and increasing prevalence of conditions like Alzheimer's and dementia. Innovation and effective treatments are in high demand.
Positioning
CervoMed is positioning itself as a leader in developing treatments for neurodegenerative diseases through its focus on novel therapeutic approaches. They're focusing on diseases with high unmet needs.
Total Addressable Market (TAM)
The total addressable market for Alzheimer's disease is estimated to be in the tens of billions of dollars annually. CervoMed's position within this TAM depends on the success of neflamapimod in clinical trials and subsequent commercialization.
Upturn SWOT Analysis
Strengths
- Innovative drug candidate (Neflamapimod)
- Experienced management team
- Focus on high unmet medical needs
- Strong intellectual property portfolio
Weaknesses
- Reliance on single drug candidate
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- No revenue stream
Opportunities
- Positive clinical trial results for neflamapimod
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
- Increasing market demand for effective treatments
Threats
- Failure of neflamapimod in clinical trials
- Competition from other companies developing similar therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- ABBV
- LLY
- BIIB
Competitive Landscape
CervoMed faces competition from larger, more established pharmaceutical companies with greater resources. Its advantage lies in its innovative drug candidate and focus on specific neurodegenerative diseases.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of neflamapimod through clinical trials.
Future Projections: Future growth is dependent on the successful completion of clinical trials and potential commercialization of neflamapimod. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include the initiation of Phase 3 clinical trials and efforts to secure additional funding.
Summary
CervoMed is a clinical-stage company with a promising drug candidate in neflamapimod. The company's success hinges on the positive outcomes of its late-stage clinical trials. It faces stiff competition from larger, better-resourced companies. Successful clinical trials can lead to partnerships and commercial success, while failure would significantly impact the company's future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CervoMed Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2016-01-04 | Co-Founder, CEO, President & Director Dr. John J. Alam M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.cervomed.com |
Full time employees 15 | Website https://www.cervomed.com | ||
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.